{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:20:48Z","timestamp":1789417248811,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ccm.2013.08.002","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T16:52:28Z","timestamp":1385052748000},"page":"867-880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel Medical Therapies for Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"34","author":[{"given":"Caroline","family":"O\u2019Connell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot S.","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2013.08.002_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrcardio.2011.104","article-title":"Treatment of pulmonary arterial hypertension with targeted therapies","volume":"8","author":"O'Callaghan","year":"2011","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.ccm.2013.08.002_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccm.2013.08.002_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1016\/j.ccm.2013.08.002_bib4","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2013.08.002_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension","volume":"30","author":"Humbert","year":"2007","journal-title":"Eur Respir J"},{"issue":"19","key":"10.1016\/j.ccm.2013.08.002_bib6","first-page":"233","article-title":"New drugs for pulmonary hypertension","volume":"57","author":"O'Connell","year":"2012","journal-title":"Eur Respir Monogr"},{"key":"10.1016\/j.ccm.2013.08.002_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.00104612","article-title":"Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial","author":"Raghu","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ejps.2009.09.005","article-title":"Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan","volume":"38","author":"Kummer","year":"2009","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"10.1016\/j.ccm.2013.08.002_bib10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","article-title":"Macitentan: entry-into-humans study with a new endothelin receptor antagonist","volume":"67","author":"Sidharta","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ccm.2013.08.002_bib11","first-page":"1066","article-title":"Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis","volume":"11","author":"Raja","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.ccm.2013.08.002_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2013.08.002_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccm.2013.08.002_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2013.08.002_bib15","unstructured":"US NIH ClinicalTrials.gov. Study of a new thermo stable formulation of epoprostenol sodium to treat\u00a0pulmonary arterial hypertension (PAH). Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01462565?term=veletri&rank=12011. Last updated October 18, 2012. Last Accessed September 29, 2013."},{"key":"10.1016\/j.ccm.2013.08.002_bib16","article-title":"EPITOME-2, An open-label study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from Flolan","author":"Sitbon","year":"2012","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1016\/j.ccm.2013.08.002_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2013.08.010","article-title":"Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class\u00a0IV: Insights from the REVEAL registry","author":"Farber","year":"2013","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.ccm.2013.08.002_bib18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.08.002_bib19","unstructured":"US NIH ClinicalTrials.gov. A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension (FREEDOM-C2). Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00887978?term=FREEDOM-C2&rank=12011. Last updated December 7, 2012. Last Accessed September 29, 2013."},{"key":"10.1016\/j.ccm.2013.08.002_bib20","unstructured":"United Therapeutics. UT-15C treprostinil diethanolamine sustained release tablets (oral treprostinil). Available at: http:\/\/www.unither.com\/oral-treprostinil-for-pah. Last Accessed September 29, 2013."},{"key":"10.1016\/j.ccm.2013.08.002_bib21","unstructured":"US NIH ClinicalTrials.gov. FREEDOM - M: oral treprostinil as monotherapy for the treatment of pulmonary arterial hypertension (PAH). Available at:\u00a0http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00325403?term=FREEDOM-M&rank=12012. Last updated February 12, 2013. Last Accessed September 29, 2013."},{"key":"10.1016\/j.ccm.2013.08.002_bib22","unstructured":"US NIH ClinicalTrials.gov. Trial of the early combination of oral treprostinil with a PDE-5 inhibitor or ERA in subjects with pulmonary arterial hypertension (FREEDOM-Ev) [Internet]. Available at: www.clinicaltrials.gov\/ct2\/show\/NCT01560624?term=FREEDOM-Ev&;rank=1. Last updated September 20, 2013. Last Accessed September 29, 2013."},{"issue":"12","key":"10.1016\/j.ccm.2013.08.002_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.08.002_bib24","unstructured":"US NIH Clinicaltrials.gov. A multinational, multicenter study to assess the efficacy and safety of BPS-314d-MR in subjects with pulmonary arterial hypertension currently receiving treatment with an\u00a0endothelin receptor antagonist and or a phosphodiesterase-5 inhibitor. Available at: clinicaltrialsfeeds.org\/clinical-trials\/show\/NCT01458236. Last updated September 26, 2013. Last Accessed September 29, 2013."},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pupt.2008.11.009","article-title":"Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension","volume":"22","author":"Voswinckel","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"Kuwano","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"issue":"122","key":"10.1016\/j.ccm.2013.08.002_bib29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1183\/09059180.00006411","article-title":"Looking to the future: a new decade of pulmonary arterial hypertension therapy","volume":"20","author":"McLaughlin","year":"2011","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ccm.2013.08.002_bib30","unstructured":"US NIH ClinicalTrials.gov. ACT-293987 in pulmonary arterial hypertension. Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01106014?term=GRIPHON&rank=1. Last updated September 3, 2013. Last Accessed September 29, 2013."},{"issue":"19","key":"10.1016\/j.ccm.2013.08.002_bib31","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMct0904473","article-title":"Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension","volume":"361","author":"Archer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccm.2013.08.002_bib32","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0002-9149(03)00910-X","article-title":"Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension","volume":"92","author":"Ivy","year":"2003","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ccm.2013.08.002_bib33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1378\/chest.109.6.1545","article-title":"Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests","volume":"109","author":"Channick","year":"1996","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.ccm.2013.08.002_bib34","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ccm.2013.08.002_bib35","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccm.2013.08.002_bib36","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuint.2004.03.016","article-title":"Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5)","volume":"45","author":"Corbin","year":"2004","journal-title":"Neurochem Int"},{"issue":"18","key":"10.1016\/j.ccm.2013.08.002_bib37","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/hrt.2009.169417","article-title":"Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study","volume":"95","author":"Jing","year":"2009","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.ccm.2013.08.002_bib38","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2013.08.002_bib39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent\u00a0stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ccm.2013.08.002_bib41","doi-asserted-by":"crossref","first-page":"e43433","DOI":"10.1371\/journal.pone.0043433","article-title":"The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats","volume":"7","author":"Lang","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib42","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.08.002_bib43","article-title":"Riociguat for the treatment of pulmonary arterial hypertension (PAH): a phase III long-term extension study (PATENT-2)","author":"Rubin","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.08.002_bib44","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.08.002_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2013.08.002_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ccm.2013.08.002_bib47","unstructured":"US NIH ClinicalTrials.gov. Evaluation of the pharmacodynamic effect of the combination of sildenafil and riociguat on blood pressure and other safety parameters (PATENT PLUS). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01179334. Last updated May 21, 2013. Last Accessed September 29, 2013."},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCHEARTFAILURE.111.964494","article-title":"Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension","volume":"5","author":"de Man","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10.1016\/j.ccm.2013.08.002_bib49","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.amjcard.2012.01.368","article-title":"Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension","volume":"109","author":"So","year":"2012","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","article-title":"Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension","volume":"178","author":"Perros","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccm.2013.08.002_bib51","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.ccm.2013.08.002_bib52","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccm.2013.08.002_bib53","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ccm.2013.08.002_bib54","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1172\/JCI32373","article-title":"An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic","volume":"117","author":"Fern\u00e1ndez","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.ccm.2013.08.002_bib55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ccm.2013.08.002_bib56","unstructured":"US NIH ClinicalTrials.gov. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01179737?term=Nilotinib+pulmonary&rank=12010. Last updated March 25, 2013. Last Accessed September 29, 2013."},{"issue":"2","key":"10.1016\/j.ccm.2013.08.002_bib57","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1152\/physiolgenomics.00169.2007","article-title":"Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension","volume":"33","author":"Moreno-Vinasco","year":"2008","journal-title":"Physiol Genomics"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2009.217","article-title":"A\u00a0dosing\/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension","volume":"87","author":"Gomberg-Maitland","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib59","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1183\/09031936.00075211","article-title":"Whistleblowers","volume":"38","author":"Humbert","year":"2011","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.ccm.2013.08.002_bib60","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by Dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension","volume":"99","author":"Herve","year":"1995","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.ccm.2013.08.002_bib62","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm764","article-title":"Function of the\u00a0serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension","volume":"8","author":"Launay","year":"2002","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib63","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/bjp.2008.241","article-title":"Pulmonary hypertension: therapeutic targets within the serotonin system","volume":"155","author":"Dempsie","year":"2008","journal-title":"Br\u00a0J Pharmacol"},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2013.08.002_bib65","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI200112805","article-title":"Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension","volume":"108","author":"Eddahibi","year":"2001","journal-title":"J\u00a0Clin Invest"},{"issue":"15","key":"10.1016\/j.ccm.2013.08.002_bib66","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/01.CIR.0000091409.53101.E8","article-title":"Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease","volume":"108","author":"Eddahibi","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ccm.2013.08.002_bib67","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1440-1681.2009.05168.x","article-title":"Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats","volume":"36","author":"Zhai","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib68","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1378\/chest.08-2823","article-title":"Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension","volume":"136","author":"Shah","year":"2009","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ccm.2013.08.002_bib69","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","article-title":"Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"37","author":"Dumitrascu","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.08.002_bib70","first-page":"A2496","article-title":"Proof-of-concept study to investigate the efficacy, haemodynamics and tolerability of teguride vs placebo in subjects with pulmonary arterial hypertension: results of a double-blind randomised, prospective IIa study","volume":"185","author":"Ghofrani","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.00105807","article-title":"Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion","volume":"31","author":"Hamidi","year":"2008","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ccm.2013.08.002_bib72","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.106.681718","article-title":"Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene","volume":"115","author":"Said","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.08.002_bib73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1465-9921-12-141","article-title":"VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension","volume":"12","author":"Hamidi","year":"2011","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.ccm.2013.08.002_bib74","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI17500","article-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","volume":"111","author":"Petkov","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccm.2013.08.002_bib75","doi-asserted-by":"crossref","unstructured":"Galie N, Badesch D, Fleming T, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH): results from a phase II study. http:\/\/dx.doi.org\/10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A2516.","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A2516"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib76","first-page":"1446","article-title":"Simvastatin treatment of pulmonary hypertension: an observational case series","volume":"127","author":"Kao","year":"2005","journal-title":"Chest"},{"issue":"31","key":"10.1016\/j.ccm.2013.08.002_bib77","doi-asserted-by":"crossref","first-page":"21926","DOI":"10.1074\/jbc.274.31.21926","article-title":"3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)","volume":"274","author":"Laufs","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib78","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.00143508","article-title":"Simvastatin and sildenafil combine to attenuate pulmonary hypertension","volume":"34","author":"Zhao","year":"2009","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ccm.2013.08.002_bib79","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1164\/rccm.2009111-699OC","article-title":"Simvastatin as a treatment for pulmonary hypertension trial (SiPHT)","volume":"181","author":"Wilkins","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"25","key":"10.1016\/j.ccm.2013.08.002_bib80","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1161\/CIRCULATIONAHA.110.015693","article-title":"Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT","volume":"123","author":"Kawut","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib81","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1183\/09031936.00149011","article-title":"Atorvastatin in pulmonary arterial hypertension (APATH) study","volume":"40","author":"Zeng","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib82","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00005344-199803000-00006","article-title":"Long-term effects of cicletanine on secondary pulmonary hypertension","volume":"31","author":"Saadjian","year":"1998","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.ccm.2013.08.002_bib83","unstructured":"US NIH ClinicalTrials.gov. Study of cicletanine for pulmonary arterial hypertension (PAH). Available at: www.clinicaltrials.gov\/show\/NCT\/00832507. Last updated August 22, 2012. Last Accessed September 29, 2013."},{"issue":"12","key":"10.1016\/j.ccm.2013.08.002_bib84","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.200805-691OC","article-title":"RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling","volume":"179","author":"Guilluy","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib85","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/bjp.2008.239","article-title":"Therapeutic potential of RhoA\/Rho kinase inhibitors in pulmonary hypertension","volume":"155","author":"Oka","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.RES.0000111804.34509.94","article-title":"Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats","volume":"94","author":"Abe","year":"2004","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib87","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/hrt.2003.029470","article-title":"Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension","volume":"91","author":"Fukumoto","year":"2005","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157489011794578491","article-title":"Latest therapeutic novelties and patents in pulmonary hypertension","volume":"6","author":"Hardavella","year":"2011","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib89","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1183\/09031936.00140309","article-title":"Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension","volume":"36","author":"Dahal","year":"2010","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ccm.2013.08.002_bib90","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.RES.0000145360.16770.9f","article-title":"Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis","volume":"95","author":"McMurtry","year":"2004","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib91","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/13543781003727099","article-title":"New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation","volume":"19","author":"Dewachter","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ccm.2013.08.002_bib92","unstructured":"US NIH ClinicalTrials.gov. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01083524?term=Dichloroacetate&rank=1. 2010. Last updated November 3, 2011. Last Accessed September 29, 2013."},{"issue":"2","key":"10.1016\/j.ccm.2013.08.002_bib93","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.coph.2010.12.002","article-title":"ACE2, a promising therapeutic target for pulmonary hypertension","volume":"11","author":"Shenoy","year":"2011","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib94","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/ar3012","article-title":"Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases","volume":"12","author":"Takahashi","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib95","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000346884","article-title":"The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease","volume":"124","author":"Dai","year":"2013","journal-title":"Cardiology"},{"issue":"2","key":"10.1016\/j.ccm.2013.08.002_bib96","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/HYPERTENSIONAHA.108.125468","article-title":"Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer","volume":"54","author":"Yamazato","year":"2009","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ccm.2013.08.002_bib97","doi-asserted-by":"crossref","first-page":"L474","DOI":"10.1152\/ajplung.00202.2011","article-title":"Cytoskeletal defects in BMPR2-associated pulmonary arterial hypertension","volume":"302","author":"Johnson","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"11","key":"10.1016\/j.ccm.2013.08.002_bib98","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1164\/rccm.200811-1678OC","article-title":"Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension","volume":"179","author":"Ferreira","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.ccm.2013.08.002_bib99","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/0961203307087610","article-title":"Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report","volume":"17","author":"Hennigan","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.ccm.2013.08.002_bib100","unstructured":"US NIH ClinicalTrials.gov. Rituximab for treatment of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Available at: clinicaltrials.gov\/ct2\/show\/NCT01086540. 2013. Last updated August 17, 2013. Last Accessed September 29, 2013."},{"issue":"20","key":"10.1016\/j.ccm.2013.08.002_bib101","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/hmg\/ddn214","article-title":"Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue","volume":"17","author":"Sobolewski","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.ccm.2013.08.002_bib102","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1165\/rcmb.2013-0100OC","article-title":"Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension","volume":"49","author":"Drake","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib103","doi-asserted-by":"crossref","first-page":"e005157","DOI":"10.1161\/JAHA.112.005157","article-title":"Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology","volume":"2","author":"Meloche","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.ccm.2013.08.002_bib104","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1165\/rcmb.2012-0429OC","article-title":"Rapamycin reverses pulmonary-artery smooth-muscle-cell proliferation in pulmonary hypertension","volume":"48","author":"Houssaini","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.112.103176","article-title":"Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid","volume":"126","author":"Zhao","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccm.2013.08.002_bib106","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1164\/rccm.201007-1106OC","article-title":"Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats","volume":"183","author":"Bogaard","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/01902148.2010.512972","article-title":"Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension","volume":"37","author":"Robbins","year":"2011","journal-title":"Exp Lung Res"},{"issue":"1","key":"10.1016\/j.ccm.2013.08.002_bib108","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00662.2006","article-title":"Biology of bone marrow-derived endothelial cell precursors","volume":"292","author":"Schatteman","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"10.1016\/j.ccm.2013.08.002_bib109","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2011-06-358374","article-title":"Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension","volume":"119","author":"Launay","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccm.2013.08.002_bib110","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1183\/09031936.00045710","article-title":"Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension","volume":"37","author":"Gambaryan","year":"2011","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ccm.2013.08.002_bib111","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000157672.70560.7b","article-title":"Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease","volume":"96","author":"Zhao","year":"2005","journal-title":"Circ Res"},{"issue":"14","key":"10.1016\/j.ccm.2013.08.002_bib112","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jacc.2006.12.037","article-title":"Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial","volume":"49","author":"Wang","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.08.002_bib113","unstructured":"US NIH ClinicalTrials.gov. Pulmonary hypertension: assessment of cell therapy (PHACeT). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00469027?term=PHACeT&rank=12010. Last updated March 7, 2013. Last Accessed September 29, 2013."}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523113001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523113001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:51:32Z","timestamp":1759452692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523113001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0272523113001020"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2013.08.002","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Medical Therapies for Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2013.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}